20/20 Biolabs Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $4.4M
- Price
- $0.3435
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.54%
- Volume
- 82.9K
About
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Quick stats
Shares outstanding12.8M
Computed float11.3M
Float / shares88.8%
Cash runway (months)11.1
Key info
SectorHealthcare
IndustryMedical - Care Facilities
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001139685
Websitehttps://2020biolabs.com
AI Summary
AI-generated1/36
minorbullishoperations update
HEALWELL AI Provides Research Update on Peer-Reviewed MyHealthNB Study and Global Recognition of DARWEN(TM)
Peer-reviewed research in the Journal of Medical Internet Research found VeroSource's MyHealthNB platform was associated with statistically significant improvements in patient empowerment, with at least 65% of respondents reporting feeling more active in their care.
Separately, HEALWELL's DARWEN(TM) AI abstract was selected as one of just 10 additional submissions featured in the HealthAI Global Governance Forum 2026's "Beyond the Room" digital programme in London on November 18, 2026.
Neither development includes new financial figures or contracts, but the company says the third-party validation can support ongoing engagement with health systems and governments.